Shopping Cart
- Remove All
Your shopping cart is currently empty
Ustekinumab
Catalog No. T9913Cas No. 815610-63-0
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
Ustekinumab
Catalog No. T9913Cas No. 815610-63-0
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $455 | In Stock | |
| 5 mg | $1,060 | In Stock | |
| 10 mg | $1,430 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Ustekinumab"
Sodium Thiocyanate
T8033540-72-7
Sodium Thiocyanate, one of the main sources of the thiocyanate anion, is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals.
- $39
Size
QTY
Disulfiram
Cited
Tetraethylthiuram disulfide, TETD, NSC 190940
T005497-77-8
Disulfiram (TETD) is an inhibitor of the acetaldehyde dehydrogenase ALDH, inhibiting hALDH1 and hALDH2 (IC50=0.15/1.45 μM) with specificity. Disulfiram is acutely sensitized to alcohol and also inhibits GSDMD pore formation.
- $50
Size
QTY
CitedBalsalazide sodium hydrate
Balsalazide disodium salt dihydrate, Balsalazide disodium dihydrate, Balsalazide disodium
T4615150399-21-6
Balsalazide sodium hydrate (Balsalazide disodium) is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.Balsalazide sodium hydrate is a new 5-aminosalicylic acid (5-ASA) containing prodrug. High dose Balsalazide sodium hydrate(3.0 g twice daily) was superior in maintaining remission in patients with ulcerative colitis compared with a low dose (1.5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated [1]. Balsalazide sodium hydrate is approved for the treatment of mild-to-moderate active UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile, with the added advantages of greater efficacy of remission induction and rapidity of onset [2].
- $39
Size
QTY
Apilimod
STA 5326
T2018541550-19-0
Apilimod (STA 5326) inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
- $43
Size
QTY
Deucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
Apilimod mesylate
STA 5326 mesylate
T3533870087-36-8
Apilimod mesylate (STA 5326 mesylate) is a potent IL-12/IL-23 inhibitor.
- $55
Size
QTY
SMA12b, SMA 12b
T248051496553-39-9In house
SMA-12b is an analog of the immunomodulatory parasite product ES-62 that has immunomodulatory activity, can modify the expression of many inflammatory response genes, increase the expression of many genes related to antioxidant responses, and can be used in the study of rheumatoid arthritis (RA) and other autoimmune diseases.
- $293
Size
QTY
Muscone Cited
Methylexaltone, 3-Methylcyclopentadecanone
T2893541-91-3
Muscone (3-Methylcyclopentadecanone) is an organic compound that is the primary contributor to the odor of musk.
- $39
Size
QTY
CitedHydrocortisone hemisuccinate
hydrocortisone 21-hemisuccinate*free acid, Hydrocortisone 21-hemisuccinate, Hydrocortisone 21-he
T46022203-97-6
Hydrocortisone hemisuccinate (hydrocortisone 21-hemisuccinate*free acid) is a corticosteroid used as an analytical and chromatography reagent.
- $30
Size
QTY
JAK2/STAT3-IN-1
T727542485758-50-5In house
JAK2/STAT3-IN-1 is a GP130 inhibitor with anti-tumor effects and can be used to study inflammation, autoimmunity and cancer.
- $293
Size
QTY
Fibrinogen
T783679001-32-5
Fibrinogen is a heterodimeric protein that can be cleaved by thrombin. Fibrinogen is a potential marker for cardiovascular disease and plays an important role in metabolism. Its absence can cause fibrinogenemia.
- $40
Size
QTY
Vidofludimus Cited
SC12267, 4sc-101
T2601717824-30-1
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
- $54
Size
QTY
CitedSelect Batch
Concentration:89.0 mg/mL
Purity:99.70%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. |
| Cell Research | HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200 μg/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 min at 37°C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope[2]. |
| Molecular Weight | 148 kDa |
| Cas No. | 815610-63-0 |
Storage & Solubility Information
| Storage | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ustekinumab | purchase Ustekinumab | Ustekinumab cost | order Ustekinumab | Ustekinumab chemical structure | Ustekinumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.